The first bellwether trial in In re Bard Implanted Port Catheter Products Liability Litigation (MDL 3081) ended in May 2026 with a result that neither side can fully claim as a victory — and that ambiguity is precisely what makes the outcome so significant for the more than 3,400 plaintiffs still waiting in line. A split verdict in Cook v. Becton Dickinson gave Bard a partial win on failure-to-warn claims while leaving the critical design-defect question unresolved through a hung jury. With a second bellwether scheduled for July 7, 2026, court-ordered settlement discussions on the horizon, and a new trial motion still pending, the Bard PowerPort lawsuit has entered its most consequential phase yet.
What the Cook v. Becton Dickinson Verdict Actually Means
The first Cook bellwether trial began on April 21, 2026, when plaintiff Robert Cook alleged that a Bard PowerPort implanted port catheter caused him a serious infection. After weeks of testimony, the jury returned a verdict that legal analysts are calling a “split decision with a loaded footnote.” The jury found Bard and its parent company Becton Dickinson not liable on the failure-to-warn claim, the failure-to-instruct claim, and a related consumer fraud allegation. Those were meaningful wins for the defense — failure-to-warn is often the backbone of pharmaceutical and medical device litigation.
However, the jury hung entirely on the two most consequential questions: whether the PowerPort was defectively designed, and whether the defendants engaged in unlawful trade practices. Perhaps more telling than the hung verdict itself is what jurors reportedly communicated afterward — that they would have answered yes if asked whether the PowerPort could have been made safer. That is not a defense win on design defect. That is a design-defect claim that survived its first courtroom encounter and lives to fight another day. For anyone using a medical malpractice calculator to estimate potential damages in a defective device case, the distinction between a verdict and a hung jury matters enormously — a hung jury resets the clock rather than closing the door.
Becton Dickinson stated as far back as 2023 that it found no new safety risks associated with the PowerPort and that it had clearly communicated the device’s risks and benefits to medical professionals. The Cook verdict gives the company some ammunition to support that narrative on the warning side — but the unresolved design-defect theory means the company cannot yet declare that its product has been cleared by a jury on its most fundamental allegation.
What a Hung Jury on Design Defect Really Signals for 3,400+ Plaintiffs
To understand the litigation landscape, it helps to distinguish between the types of claims at issue in the Bard PowerPort lawsuit. Plaintiffs across MDL 3081 allege that the PowerPort’s design causes catheter fracture, migration, thrombosis, embolization, and infection — particularly in long-term intravenous therapy patients, including those undergoing chemotherapy. The Cook case was an infection case, and infection cases are now widely regarded among mass tort observers as the harder category for plaintiffs to win, based on the first trial’s outcome.
Upcoming bellwether trials are expected to focus on catheter fracture and thrombosis injuries — claims that many legal analysts consider factually stronger for the plaintiff side. Six bellwether trials are scheduled between March 2026 and February 2027, covering the full spectrum of infection, fracture, and thrombosis claims. The Cook result, while not a plaintiff victory, did not collapse the litigation. It confirmed that design defect — the theory most relevant to fracture and thrombosis cases — remains a live and viable claim. For the full docket history and MDL case filings, Justia maintains public MDL records that can help plaintiffs and researchers track procedural developments in real time.
The table below summarizes the current state of the Bard PowerPort MDL as of June 2026:
| Data Point | Detail | Source |
|---|---|---|
| MDL Name | In re Bard Implanted Port Catheter Products Liability Litigation (MDL 3081) | D. Arizona, Judge David G. Campbell |
| MDL Consolidated | August 2023 | D. Arizona Court Records |
| Active Cases (June 2026) | 3,376–3,400+ | Lawsuit Information Center; Drugwatch, June 2026 |
| First Bellwether Trial | Cook v. Becton Dickinson — began April 21, 2026 (infection case) | AboutLawsuits.com; Seeger Weiss |
| First Verdict Outcome | Defense win on failure-to-warn; hung jury on design defect | Lawsuit Information Center; Seeger Weiss |
| New Trial Motion Status | Filed by plaintiffs; Bard reply due July 1, 2026 | Drugwatch, June 10, 2026 |
| Second Bellwether Date | July 7, 2026 (status uncertain — original plaintiff Wanda Miller died Feb. 2, 2026) | Drugwatch, June 2026 |
| Settlement Talks Ordered | July 2026 (court-directed, no global settlement as of June 2026) | TorHoerman Law; Drugwatch |
| Estimated Settlement Range | $10,000–$300,000 per case; up to $1,000,000 for most severe injuries | TorHoerman Law; Drugwatch |
| Total Bellwether Trials Scheduled | Six trials, March 2026 through February 2027 | Seeger Weiss; Miller & Zois |
The July 7 Bellwether Complication and the New Judge Assignment
The second bellwether in MDL 3081 was originally set for July 7, 2026, with plaintiff Wanda Miller’s case serving as the test case. However, Miller passed away on February 2, 2026, creating both a procedural and human complexity. The presiding judge is still deciding whether Miller’s case will remain in the bellwether pool or be replaced by another plaintiff’s matter. A new judge has also been assigned to oversee the second bellwether trial, which introduces additional variables into how the proceedings will be managed.
This kind of mid-stream complication is not unusual in large medical device MDLs, but it adds pressure to an already compressed timeline. The court has simultaneously directed both parties into settlement discussions scheduled for July 2026 — meaning the legal system is essentially running two parallel tracks at once: continued trial preparation and structured settlement negotiation. That dual-track approach is a signal that Judge Campbell’s court wants to create conditions for resolution without forcing one. For context on how federal courts manage mass tort settlements and bellwether processes, the U.S. Courts system publishes caseload statistics and procedural guidance on MDL management that explains the legal framework behind these procedures.
The July 2026 settlement discussions are court-ordered, not voluntary — a meaningful distinction. It suggests the court believes the parties have enough information from the first trial to begin meaningful valuation conversations, even without a clean jury verdict to anchor damages expectations.
Settlement Valuation and What Plaintiffs Should Realistically Expect
No global settlement has been reached in the Bard PowerPort lawsuit as of June 2026. That is expected at this stage — most large medical device MDLs do not begin serious global settlement negotiations until at least two or three bellwether trials have produced verdicts that allow both sides to calibrate their exposure. With one hung design-defect verdict and five more bellwethers ahead, the litigation is still in its signal-gathering phase.
Attorney estimates for individual settlement payouts currently range from $10,000 to $300,000 per case, with the most severe injury cases — particularly those involving permanent disability, major surgery, or death — potentially reaching $1,000,000. Those estimates will shift materially depending on how the next two or three bellwether trials conclude. A plaintiff win on design defect in a fracture or thrombosis case could substantially increase settlement leverage across the entire docket. A second defense win could push valuations down and embolden Becton Dickinson to continue litigating. Plaintiffs evaluating their position in any mass tort — including this one — should understand that a personal injury settlement calculator can provide a baseline framework for understanding how injury severity, medical costs, and liability strength interact to shape compensation ranges.
The MDL took approximately 31 months from its August 2023 consolidation to the first bellwether trial in April 2026 — a timeline consistent with typical medical device MDL trajectories, according to publicly available MDL benchmarking data. Plaintiffs who have already filed should remain in contact with their attorneys as the second bellwether and settlement discussions approach. Those who have not yet filed should understand that MDL consolidation cut-off dynamics and statutes of limitations vary by state. The Cornell Legal Information Institute’s explanation of statutes of limitations provides a useful primer on how these deadlines work and why timing matters in mass tort litigation.
For plaintiffs whose injuries resulted in a fatal outcome — whether from a severe infection, catheter embolization, or another PowerPort-related complication — the litigation calculus involves wrongful death claims that carry distinct legal standards and damages frameworks. Families in that situation can use a wrongful death calculator to begin understanding how economic loss, loss of consortium, and other damages categories are typically valued in device-related fatality cases.
What Comes Next: Key Milestones Through July 2026 and Beyond
The Bard PowerPort lawsuit is now moving through a sequence of overlapping events that will largely define the trajectory of all 3,400+ pending cases. Here is what to watch through the remainder of 2026:
- July 1, 2026: Bard’s deadline to file its reply to plaintiffs’ motion for a new trial in the Cook case. If granted, the design-defect claim gets a fresh jury. If denied, the hung jury stands as an inconclusive result.
- July 7, 2026: The second bellwether trial is scheduled to begin, though the substitution or retention of Wanda Miller’s case as the lead vehicle remains pending before the newly assigned judge.
- July 2026: Court-ordered settlement discussions between plaintiffs and Becton Dickinson are scheduled to take place. These discussions will not necessarily produce a deal, but they create a structured environment for global resolution conversations to begin in earnest.
- March 2026–February 2027: The full six-trial bellwether schedule will progressively test infection, fracture, and thrombosis theories before different juries, giving both sides increasingly refined data on litigation risk.
The central takeaway from the Cook verdict is that the Bard PowerPort lawsuit is neither over nor stalled. The defense won on warnings, but the jury’s implicit validation of the “could have been made safer” argument is exactly the kind of signal that keeps mass tort litigation moving toward settlement. With court-ordered talks in July 2026 and five more trials ahead, the next six months will be the defining period for this MDL.
Frequently Asked Questions About the Bard PowerPort Lawsuit
What did the first Bard PowerPort bellwether trial verdict actually decide?
The Cook v. Becton Dickinson trial concluded in May 2026 with a split outcome. The jury found Bard not liable on the failure-to-warn, failure-to-instruct, and consumer fraud claims. However, the jury hung — meaning it could not reach a unanimous decision — on the critical design-defect claim and the unlawful trade practices allegation. Jurors reportedly indicated they believed the PowerPort could have been made safer, which means the design-defect theory was not defeated; it simply did not produce a verdict either way. This leaves the most important question in the Bard PowerPort lawsuit unresolved and subject to either a new trial or future bellwether resolution.
How many cases are currently pending in the Bard PowerPort MDL?
As of June 2026, there are between 3,376 and 3,400+ active cases consolidated in MDL 3081, In re Bard Implanted Port Catheter Products Liability Litigation, in the U.S. District Court for the District of Arizona before Judge David G. Campbell. The MDL was formed in August 2023, and the case volume has grown substantially since then. Cases involve a range of alleged injuries including catheter fracture, migration, thrombosis, embolization, and infection — primarily in patients who received the PowerPort for long-term intravenous therapy.
What is the expected Bard PowerPort settlement amount?
No global settlement has been reached as of June 2026, so any figures are estimates based on attorney projections and injury severity. Individual settlement payouts are currently estimated to range from $10,000 to $300,000 per case, depending on the severity of the injury, documented medical costs, and the strength of the liability evidence. Cases involving the most severe injuries — including permanent disability or death — could potentially reach $1,000,000 or more. These estimates are subject to change as additional bellwether trial verdicts provide both sides with better data to assess litigation risk. Court-ordered settlement discussions are scheduled for July 2026.
What happens at the July 2026 second bellwether trial?
The second bellwether in MDL 3081 is scheduled to begin on July 7, 2026. However, the original plaintiff, Wanda Miller, died on February 2, 2026, and the court is still determining whether her case will remain in the bellwether pool or be replaced by another plaintiff’s matter. A new judge has been assigned to preside over the second trial. Unlike the first Cook case — which was an infection case — upcoming bellwether trials are expected to focus on catheter fracture and thrombosis injuries, which many legal analysts consider stronger theories for plaintiffs based on the first trial’s outcome on infection-related claims.
Should I still file a Bard PowerPort lawsuit in 2026 if I was injured?
If you believe you suffered an injury — such as catheter fracture, thrombosis, infection, or migration — related to a Bard PowerPort implanted port catheter, the time to evaluate your legal options is now. Statutes of limitations vary by state and begin running from the date of injury or the date you discovered (or reasonably should have discovered) the connection between your injury and the device. The existence of an active MDL with court-ordered settlement discussions in July 2026 means the litigation is at a pivotal stage. Waiting too long risks missing applicable filing deadlines. Consulting a qualified mass tort attorney promptly is essential to preserving your legal rights.
This content is for general informational purposes only and does not constitute legal advice, create an attorney-client relationship, or substitute for consultation with a licensed attorney in your jurisdiction.
Related reading: medical malpractice calculator
Related reading: wrongful death calculator
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.